Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 02, 2023 16:01 ET | Source: Vaxart, Inc.

Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results

Norovirus challenge study topline results indicate the potential of Vaxart’s oral pill vaccine candidate to reduce rates of norovirus infection, norovirus acute gastroenteritis and viral shedding ...
November 02, 2023 08:00 ET | Source: Vaxart, Inc.

Vaxart Doses First Subject in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers

Trial evaluating the ability of oral vaccine tablets to induce breast milk antibodies and transfer of antibodies to young infants SOUTH SAN FRANCISCO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) --...
October 26, 2023 08:00 ET | Source: Vaxart, Inc.

Vaxart to Host Third Quarter 2023 Business Update and Financial Results Conference Call on November 2

Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report...
October 11, 2023 08:00 ET | Source: Vaxart, Inc.

Vaxart to Present at World Vaccine Congress Europe 2023 on October 18-19

SOUTH SAN FRANCISCO, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James F. Cummings,...
September 21, 2023 08:00 ET | Source: Vaxart, Inc.

Vaxart to Participate in Fireside Chat at 2023 Cantor Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that senior management will participate in a fireside chat at the 2023 Cantor Global...
September 06, 2023 16:05 ET | Source: Vaxart, Inc.

Vaxart Announces Topline Data from the Phase 2 Challenge Study of its Monovalent Norovirus Vaccine Candidate

Study met 5 of 6 primary endpoints Vaccine was safe and well tolerated with no vaccine-related serious adverse events (SAEs) Vaccination led to a statistically significant reduction in infection...
August 03, 2023 16:01 ET | Source: Vaxart, Inc.

Vaxart Provides Business Update and Reports Second Quarter 2023 Financial Results

On track to report topline data from Phase 2 GI.1 norovirus vaccine challenge study in Q3 2023 Cash runway extended into Q3 2024 Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif.,...
July 27, 2023 08:00 ET | Source: Vaxart, Inc.

Vaxart to Host Second Quarter 2023 Business Update and Financial Results Conference Call on August 3

Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report...
July 06, 2023 08:00 ET | Source: Vaxart, Inc.

Vaxart Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate

Met all primary endpoints: Vaccine was well-tolerated with robust immunogenicity Continue to expect topline data from Phase 2 GI.1 challenge study in Q3 2023 SOUTH SAN FRANCISCO, Calif., July 06,...
June 26, 2023 16:45 ET | Source: Vaxart, Inc.

Vaxart Stockholders Approve All Four Proposals in the 2023 Proxy Statement

SOUTH SAN FRANCISCO, Calif., June 26, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today held its Annual Meeting of Shareholders in a virtual-only format. Preliminary results from the Annual...